ZA915659B - Novel piperidyl ethers and thioethers as inhibitors of cholesterol biosynthesis - Google Patents

Novel piperidyl ethers and thioethers as inhibitors of cholesterol biosynthesis

Info

Publication number
ZA915659B
ZA915659B ZA915659A ZA915659A ZA915659B ZA 915659 B ZA915659 B ZA 915659B ZA 915659 A ZA915659 A ZA 915659A ZA 915659 A ZA915659 A ZA 915659A ZA 915659 B ZA915659 B ZA 915659B
Authority
ZA
South Africa
Prior art keywords
thioethers
inhibitors
cholesterol biosynthesis
piperidyl ethers
novel piperidyl
Prior art date
Application number
ZA915659A
Other languages
English (en)
Inventor
Charlotte Louise Barney
Louise Barney Charlotte
James Ray Mccarthy
Ray Mccarthy James
Marion Woods Wannamaker
Woods Wannamaker Marion
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of ZA915659B publication Critical patent/ZA915659B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA915659A 1990-07-25 1991-07-18 Novel piperidyl ethers and thioethers as inhibitors of cholesterol biosynthesis ZA915659B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55787790A 1990-07-25 1990-07-25

Publications (1)

Publication Number Publication Date
ZA915659B true ZA915659B (en) 1992-05-27

Family

ID=24227242

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA915659A ZA915659B (en) 1990-07-25 1991-07-18 Novel piperidyl ethers and thioethers as inhibitors of cholesterol biosynthesis

Country Status (17)

Country Link
EP (1) EP0468434B1 (xx)
JP (1) JP3387513B2 (xx)
KR (1) KR100225764B1 (xx)
CN (1) CN1058399A (xx)
AT (1) ATE134626T1 (xx)
AU (1) AU644458B2 (xx)
CA (1) CA2047375C (xx)
DE (1) DE69117375T2 (xx)
ES (1) ES2086436T3 (xx)
FI (1) FI913556A (xx)
HU (1) HUT58290A (xx)
IE (1) IE912613A1 (xx)
IL (1) IL98917A0 (xx)
NO (1) NO912888L (xx)
NZ (1) NZ239022A (xx)
PT (1) PT98437A (xx)
ZA (1) ZA915659B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5348964A (en) * 1990-07-25 1994-09-20 Merrell Dow Pharmaceuticals Inc. Piperidyl ethers and thioethers as inhibitors of cholesterol biosynthesis
US5350758A (en) * 1992-07-08 1994-09-27 Merrell Dow Pharmaceuticals Inc. Piperidyl sulfonamides and sulfoxamides as inhibitors of cholesterol biosynthesis
DE4303840A1 (de) * 1992-10-22 1994-08-11 Thomae Gmbh Dr K Aryliden-1-azacycloalkane und Arylalkyl-1-azacycloalkane, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
US5466687A (en) * 1992-10-22 1995-11-14 Dr. Karl Thomae Gmbh Arylidene-1-azacycloalkanes and arylalkyl-1-azacyclo-alkanes, their salts, medicaments containing these compounds and their use, and processes for their preparation
FR2697250B1 (fr) * 1992-10-28 1995-01-20 Fournier Ind & Sante Dérivés de beta,beta-diméthyl-4-pipéridineéthanol et de 1,2,3,6-tétrahydro-beta,beta-diméthyl-4-pyridineéthanol, leur procédé de préparation et leur utilisation en thérapeutique.
DE19754795A1 (de) * 1997-12-10 1999-06-17 Boehringer Ingelheim Pharma Neue Urethane, ihre Thio- und Dithioanaloga, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
EP1216988A4 (en) 1999-09-28 2005-04-20 Nihon Nohyaku Co Ltd THIOALKYLAMINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
JP2001163854A (ja) * 1999-09-28 2001-06-19 Nippon Nohyaku Co Ltd チオアルキルアミン誘導体及びその製造方法
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
AU2008335135A1 (en) 2007-12-11 2009-06-18 Cytopathfinder, Inc. Carboxamide compounds and their use as chemokine receptor agonists
US20130072519A1 (en) 2010-05-21 2013-03-21 Edward Lee Conn 2-phenyl benzoylamides
EP2680874A2 (en) 2011-03-04 2014-01-08 Pfizer Inc Edn3-like peptides and uses thereof
CN105143203A (zh) 2013-04-17 2015-12-09 辉瑞大药厂 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CN113574055B (zh) 2019-01-18 2024-07-23 阿斯利康(瑞典)有限公司 Pcsk9抑制剂及其使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3382180A (en) * 1958-04-01 1968-05-07 Lever Brothers Ltd Detergent compositions containing sulfoxide as a suds-stabilizing agent
US4244963A (en) * 1979-09-27 1981-01-13 Merck & Co., Inc. 1-[2-(Alkyl and arylsulfonyl)-2-propenyl and propyl] substituted piperidines useful as antimicrobial and antiinflammatory agents
US5149524A (en) * 1991-01-03 1992-09-22 Rohm And Haas Company Antimicrobial polymeric quaternary ammonium salts

Also Published As

Publication number Publication date
EP0468434B1 (en) 1996-02-28
JP3387513B2 (ja) 2003-03-17
KR920002539A (ko) 1992-02-28
EP0468434A1 (en) 1992-01-29
ES2086436T3 (es) 1996-07-01
NO912888L (no) 1992-01-27
CA2047375A1 (en) 1992-01-26
CN1058399A (zh) 1992-02-05
KR100225764B1 (ko) 1999-10-15
FI913556A0 (fi) 1991-07-24
HU912486D0 (en) 1991-12-30
PT98437A (pt) 1992-05-29
FI913556A (fi) 1992-01-26
ATE134626T1 (de) 1996-03-15
NO912888D0 (no) 1991-07-24
HUT58290A (en) 1992-02-28
CA2047375C (en) 2003-04-15
DE69117375D1 (de) 1996-04-04
AU8119491A (en) 1992-01-30
JPH04234362A (ja) 1992-08-24
IL98917A0 (en) 1992-07-15
NZ239022A (en) 1993-11-25
DE69117375T2 (de) 1996-08-14
IE912613A1 (en) 1992-01-29
AU644458B2 (en) 1993-12-09

Similar Documents

Publication Publication Date Title
ZA915659B (en) Novel piperidyl ethers and thioethers as inhibitors of cholesterol biosynthesis
NZ240230A (en) Mercaptoacetylamide derivatives; preparation, use and pharmaceutical compositions thereof
IL86464A (en) 4-phosphinyl-3- hydroxybutanoic acid derivatives useful as cholesterol biosynthesis inhibitors and pharmaceutical compositions containing the same
BG105709A (en) Piperidines as ccr5 modulatiors
NZ236589A (en) A-nor-steroid-3-carboxylic acid derivatives and pharmaceutical compositions
IL99538A0 (en) Fibrinogen receptor antagonists and pharmaceutical compositions containing them
MY115339A (en) Compositions containing micronized nebivolol
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
IL101779A0 (en) Fibrinogen receptor antagonists and pharmaceutical compositions containing them
HU9403567D0 (en) Aqueous solution inclusion complexes of benzothiophene compounds with water soluble cyclodextrins, and pharmaceutical formulations and methods thereof
IL109720A (en) N-alkylthio polyamine derivatives and radioprotective compositions containing them
AU8452991A (en) 1-aryl-3-pyridinyl-2-propene-1-ones
ATE148990T1 (de) Ebastin oder ebastin-analoga enthaltende arzneimittel
ZA886097B (en) Pharmaceutical composition for the treatment of psoriasis
IL85992A0 (en) Dihydropyridinamides,their preparation and pharmaceutical compositions containing them
ZA934777B (en) Novel piperidyl amides, sulfonamides and sulfoxamides as inhibitors of cholesterol biosynthesis.
AU6415994A (en) Substituted caprolactams and derivatives thereof useful for treatment of hiv disease
UA42722C2 (uk) Сульфіди, сульфоксиди або сульфони, або їх фармацевтично прийнятні солі і фармацевтична композиція, що їх містить
NZ223293A (en) Beta-alkyl melatonins and pharmaceutical compositions
ES8504774A1 (es) Procedimiento para preparar derivados de 2-piperacinil-quinazolina
HK1023516A1 (en) Pharmaceutical composition containing stimulators of interferon-gamma
IL112099A0 (en) N-oxides of 4-arylpiperazines and 4-arylpiperidines and pharmaceutical compositions containing them
AU8452791A (en) 1-phenyl-3-aryl-2-propyne-1-ones
UA37211C2 (uk) Похідні 1,4-дигідропіридину у формі рацемату або енантіомерів, 2-хлор-3-ціанобензальдегід як проміжний продукт для їх одержання та фармацевтична композиція, що має антагоністичну активність по відношенню до катіонів кальцію
GR880100401A (el) 8α-ακυλαμινεργολινη,παρασκευη της και φαρμακευτικες συνθεσεις που την περιεχουν.